STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL DRUGS:
TOWARDS AN IMPLEMENTATION OF THE
TREATMENT PATHWAY IN ONCO-HEMATOLOGY

Ravenna Sala Corelli
26 - 27 May 2017

26th May

1 Session: to transplant or not to Transplant:
1st part 13.30 - 16.10
1) Hematopoietic Stem cell transplantation (HSCT) in the era of novel drugs: The EBMT perspective
   Duarte R, Spain
   Nagler A, Istrael
   Rambaldi A, Italy
   Bonini C, Italy
2) HSCT in acute myeloid leukemia
   Martinelli G, Italy
   Aversa F, Italy
   Luppi M, Italy
3) HSCT in Philadelphia-ALL: can we use them as a bridge to transplant
   Amadori D, Gratwohl A, Lanza F
4) Infection Control Strategy In High Risk HSCT
   No
   Yes
   Duarte R, Spain
   Lanza F, Italy
5) Endothelial complications post SCT: how can we predict and prevent it?
   No
   Yes
   Olivieri A, Italy
   McGrath E, UK
   Babic A, Italy
6) Quality management and accreditation in transplantation: is it worth doing?
7) Nurses impact on HSCT outcome

16.10 - 16.30 Coffee break

2nd part 16.30 - 19.00
1) Cell therapy for solid tumors
   Comoli P, Italy
   Necchi A, Italy
   Vliek S, Netherlands
2) HSCT for refractory-relapsed Germ cell tumor
   Bonifazi F, Pedrazzoli P, Tosi P
3) HSCT in Breast cancer
4) Debate: Mobilization of HSCT in multiple myeloma: is chemotheraphy still needed
   No
   Yes
   Duarte R, Spain
   Lanza F, Italy

10.40 - 11.00 Coffee break

27th May

2 Session: Novel drugs: too many or still not enough!
Is transplantation still the thing to do?
1st part 8.30 - 10.40
1) Novel drugs in low grade nHL: are they better than SCT
   Bay J, Pane F
   Zaja F, Italy
   Cuneo A, Italy
2) How I treat aggressive CLL
   Nagler A, Istrael
   Carestella C, Italy
3) Which is the role of Immune check point inhibitors in malignant lymphomas
4) Role of monoclonal antibodies for the management of Hodgkin’s lymphoma patients who are candidate to HSCT
   Martinelli G, Italy
   Martin M, Italy
5) Immune check point inhibitors in solid tumors with special emphasis on lung cancer: can we use it in combination with cellular therapy?
   No
   Yes
   Bennati C, Italy
   Cavo M, Italy
6) Multiple myeloma in young patients: one-two or no transplants, what is better?

11.00 - 11.30 Coffee break

2nd part 11.00 - 13.30
1) Novel Monoclonal antibodies in MM
   Bacigalupo A, Lucchesi A
   Malavasi M, Italy
2) Rethinking the treatment algorithm for Myelofibrosis: BMT Yes
   Bacigalupo A, Italy
   Barosi G, Italy
   Dufour C, Italy
3) How I treat PNH
   Hill A, UK
   Aversa F, Italy
   Buacigalupo A, Italy
4) Allogeneic HSCT for Aplastic anemia in first CR
5) Treatment of acute GVHD: Photoaheresis in first or second line?
6) HSCT in the outpatient setting: how can we manage it!

ID ECM 2007 - 185655
Ecm Credits 6.3 (Formative credits used by Italian Ministry of Health) the following professional categories may participate in the meeting
Surgeon
specialist in Hematology, Medical Genetics, Internal Medicine, Oncology, Radiotherapy, Pathological Anatomy, Medical Genetics Lab, Trasfusion Medicine, General Medicine
Biologist
Biomedical Laboratory Technicians
Nurse

Unrestricted Educational Grant